Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results

Charles C. Wykoff

doi:10.1016/j.oret.2019.07.007

Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	917-919
Number of pages	3
Journal	Ophthalmology Retina
Volume	3
Issue number	11
DOIs	https://doi.org/10.1016/j.oret.2019.07.007
State	Published - Nov 2019

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.oret.2019.07.007

Cite this

@article{dd7d4328fc354ab2980da718c0c25e1e,

title = "Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results",

author = "Wykoff, {Charles C.}",

note = "Funding Information: Financial Disclosure(s): The author(s) have made the following disclosure(s): C.C.W.: Research support ? Adverum, Allergan, Apellis, Clearside, Genentech, Novartis, Ophthotech, Opthea, Regeneron, Regenxbio, Roche, Samsung, Santen; Consulting ? Alimera, Allegro, Allergan, Apellis, Bayer, Clearside, EyePoint, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Roche, Regeneron, Regenxbio, Santen, Takeda; Speaker ? Regeneron. Obtained funding: Wykoff Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = nov,

doi = "10.1016/j.oret.2019.07.007",

language = "English (US)",

volume = "3",

pages = "917--919",

journal = "Ophthalmology Retina",

issn = "2468-6530",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision

T2 - Consideration of DRCR.Net Protocol V Results

AU - Wykoff, Charles C.

N1 - Funding Information: Financial Disclosure(s): The author(s) have made the following disclosure(s): C.C.W.: Research support ? Adverum, Allergan, Apellis, Clearside, Genentech, Novartis, Ophthotech, Opthea, Regeneron, Regenxbio, Roche, Samsung, Santen; Consulting ? Alimera, Allegro, Allergan, Apellis, Bayer, Clearside, EyePoint, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Roche, Regeneron, Regenxbio, Santen, Takeda; Speaker ? Regeneron. Obtained funding: Wykoff Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/11

Y1 - 2019/11

UR - http://www.scopus.com/inward/record.url?scp=85074183418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074183418&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2019.07.007

DO - 10.1016/j.oret.2019.07.007

M3 - Editorial

AN - SCOPUS:85074183418

SN - 2468-6530

VL - 3

SP - 917

EP - 919

JO - Ophthalmology Retina

JF - Ophthalmology Retina

IS - 11

ER -

Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this